About Janux Therapeutics
Janux Therapeutics is a company based in San Diego (United States) founded in 2017 by David Campbell. Janux Therapeutics has raised $181 million across 2 funding rounds from investors including Citadel, Orbimed and Janus Henderson Investors. The company has 81 employees as of December 31, 2024. Janux Therapeutics offers products and services including PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008). Janux Therapeutics operates in a competitive market with competitors including Sana Biotechnology, GigaGen, Kronos Bio, Carisma Therapeutics and Asher Biotherapeutics, among others.
- Headquarter San Diego, United States
- Employees 81 as on 31 Dec, 2024
- Founders David Campbell
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Janux Therapeutics, Inc.
-
Annual Revenue
$10.59 M (USD)30.99as on Dec 31, 2024
-
Net Profit
-$68.99 M (USD)-18.36as on Dec 31, 2024
-
EBITDA
-$96.79 M (USD)-36.27as on Dec 31, 2024
-
Total Equity Funding
$181 M (USD)
in 2 rounds
-
Latest Funding Round
$125 M (USD), Series B
Apr 20, 2021
-
Investors
Citadel
& 10 more
-
Employee Count
81
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Janux Therapeutics
Janux Therapeutics is a publicly listed company on the NASDAQ with ticker symbol JANX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Janux Therapeutics
Janux Therapeutics offers a comprehensive portfolio of products and services, including PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).
Tumor-activated T cell engager targeting prostate cancer
Tumor-activated T cell engager for EGFR-related cancers
People of Janux Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
21 people
Senior Team
12 people
Finance and Accounting
8 people
Operations Team
5 people
Advisor Team
5 people
Product Management Team
5 people
Software Development Team
3 people
Scientist Team
3 people
Unlock access to complete
Funding Insights of Janux Therapeutics
Janux Therapeutics has successfully raised a total of $181M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $125 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Janux Therapeutics
Janux Therapeutics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Citadel, Orbimed and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Janux Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Janux Therapeutics
Investment portfolio details for Janux Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Janux Therapeutics
Detailed financials for Janux Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Janux Therapeutics Comparisons
Peer comparison for Janux Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Janux Therapeutics
Janux Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, GigaGen, Kronos Bio, Carisma Therapeutics and Asher Biotherapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Chimeric antigen receptor macrophages are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of cancer and autoimmune diseases
|
Detailed competitors of Janux Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Janux Therapeutics
Complete news archive for Janux Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Janux Therapeutics
Janux Therapeutics was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Janux Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
David Campbell is the current CEO of Janux Therapeutics. They have also founded this company.
Janux Therapeutics is a funded company, having raised a total of $181M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Janux Therapeutics is 81.
Annual revenue of Janux Therapeutics is $10.59M as on Dec 31, 2024.
Janux Therapeutics was founded in 2017 and is headquartered in San Diego, United States. Focus is placed on the biotechnology sector, specifically oncology, where immunotherapeutics are developed for solid tumors such as colorectal, gastroesophageal, prostate, NSCLC, triple-negative breast, and ovarian cancers. Lead candidates include TROP2-TRACTr, PSMA-TRACTr, EGFR-TRACTr, HER2-TRACTr, and costim bispecifics. T cell engagers that bind tumor cells and activate patient T-cells for tumor eradication are also being advanced.
Janux Therapeutics's top competitors include Kronos Bio, Sana Biotechnology and GigaGen.
Janux Therapeutics offers PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).
Yes, Janux Therapeutics is publicly traded on NASDAQ under the ticker symbol JANX.
Janux Therapeutics has 11 investors. Key investors include Citadel, Orbimed, Janus Henderson Investors, RA Capital, and Hartford Hospital.
The ticker symbol of Janux Therapeutics is JANX on NASDAQ.